Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/?NS2/1030s in RSV-Seronegative Young Children

Background Respiratory syncytial virus (RSV) is the leading cause of pediatric lower respiratory illness (LRI) and a vaccine for immunization of children is needed. RSV/6120/& UDelta;NS2/1030s is a cDNA-derived live-vaccine candidate attenuated by deletion of the interferon antagonist NS2 gene and the genetically stabilized 1030s missense polymerase mutation in the polymerase, conferring temperature sensitivity.Methods A single intranasal dose of RSV/6120/& UDelta;NS2/1030s was evaluated in a double-blind, placebo-controlled trial (vaccine to placebo ratio, 2:1) at 105.7 plaque-forming units (PFU) in 15 RSV-seropositive 12- to 59-month-old children, and at 105 PFU in 30 RSV-seronegative 6- to 24-month-old children.Results RSV/6120/& UDelta;NS2/1030s infected 100% of RSV-seronegative vaccinees and was immunogenic (geometric mean RSV plaque-reduction neutralizing antibody titer [RSV-PRNT], 1:91) and genetically stable. Mild rhinorrhea was detected more frequently in vaccinees (18/20 vaccinees vs 4/10 placebo recipients, P = .007), and LRI occurred in 1 vaccinee during a period when only vaccine virus was detected. Following the RSV season, 5 of 16 vaccinees had & GE;4-fold rises in RSV-PRNT with significantly higher titers than 4 of 10 placebo recipients with rises (1:1992 vs 1:274, P = .02). Thus, RSV/6120/& UDelta;NS2/1030s primed for substantial anamnestic neutralizing antibody responses following naturally acquired RSV infection.Conclusions RSV/6120/& UDelta;NS2/1030s is immunogenic and genetically stable in RSV-seronegative children, but the frequency of rhinorrhea in vaccinees exceeded that in placebo recipients.Clinical Trials Registration NCT03387137. A live-attenuated intranasal RSV vaccine candidate containing a deletion of the NS2 gene and a genetically stabilized mutation in the polymerase gene induced primary and memory serum neutralizing serum antibody responses in 6- to 24-month-old RSV-seronegative children, but may be associated with rhinorrhea.